CpG Island Methylation in a Mouse Model of Lymphoma Is Driven by the Genetic Configuration of Tumor Cells

René Opavský, Shu‐Huei Wang, Prashant Trikha, Aparna Raval, Yuan Huang, Yue-Zhong Wu, Blanca Rodríguez, B Keller, Sandya Liyanarachchi, Wei Guo, Ramana V. Davuluri, Michael I. Weinstein, Dean W. Felsher, Michael C. Ostrowski, Gustavo Leone, Christoph PlassPLoS 2005

Abstract

Hypermethylation of CpG islands is a common epigenetic alteration associated with cancer. Global patterns of hypermethylation are tumor-type specific and nonrandom. The biological significance and the underlying mechanisms of tumor-specific aberrant promoter methylation remain unclear, but some evidence suggests that this specificity involves differential sequence susceptibilities, the targeting of DNA methylation activity to specific promoter sequences, or the selection of rare DNA methylation events during disease progression. Using restriction landmark genomic scanning on samples derived from tissue culture and in vivo models of T cell lymphomas, we found that MYC overexpression gave rise to a specific signature of CpG island hypermethylation. This signature reflected gene transcription profiles and was detected only in advanced stages of disease. The further inactivation of the Pten, p53, and E2f2 tumor suppressors in MYC-induced lymphomas resulted in distinct and diagnostic CpG island methylation signatures. Our data suggest that tumor-specific DNA methylation in lymphomas arises as a result of the selection of rare DNA methylation events during the course of tumor development. This selection appears to be driven by the genetic configuration of tumor cells, providing experimental evidence for a causal role of DNA hypermethylation in tumor progression and an explanation for the tremendous epigenetic heterogeneity observed in the evolution of human cancers. The ability to predict genome-wide epigenetic silencing based on relatively few genetic alterations will allow for a more complete classification of tumors and understanding of tumor cell biology.

Introduction

In cancer biology, the silencing of genes through CpG island hypermethylation is a hallmark of disease progression. These patterns are notably non-random and specific to different tumor types. However, the underlying mechanism—whether driven by sequence susceptibility, direct targeting by oncogenes, or the Darwinian selection of rare silencing events—has remained a central mystery. This study, published in PLoS Genetics, utilizes a mouse model of T-cell lymphoma to demonstrate that a tumor's specific genetic makeup dictates its "epigenetic fingerprint."

Methods

The researchers employed an inducible MYC oncogene mouse model of T-cell lymphoma. To investigate how different genetic backgrounds influence epigenetic outcomes, these mice were crossed with strains lacking key tumor suppressors: p53, Pten, or E2f2.

Key methodologies included:

  • Restriction Landmark Genomic Scanning (RLGS): A 2D gel electrophoresis technique used to visualize the methylation status of over 2,000 CpG islands simultaneously.
  • Fluorescence-Activated Cell Sorting (FACS): Used to isolate specific cell populations at different stages of disease.
  • Validation Tools: COBRA and bisulfite sequencing were used to confirm methylation status, while RT-PCR verified that hypermethylation resulted in decreased gene expression.

Key Insights and Results

The "Selection" Model of Epigenetic Silencing

A pivotal finding of the study was that precancerous cells expressing high levels of MYC showed no abnormal methylation. Distinct signatures only appeared in advanced, clonal tumors. This timing strongly refutes the "Direct Targeting" hypothesis—which suggests oncogenes actively recruit methylation machinery—and instead supports a model where rare, random methylation events are selected for based on the survival advantage they provide.

Genetic Determinism and Predictive Signatures

The loss of different tumor suppressors resulted in distinct, diagnostic methylation signatures. Using unsupervised hierarchical clustering of RLGS data, the researchers could perfectly group tumors based on their genetic background. For instance, the methylation profile alone was sufficient to distinguish a p53-deficient tumor from a Pten-deficient one.

Quantitative Differences in Epigenetic Pressure

The study found that the overall burden of hypermethylation varied significantly by genotype:

  • MYC-only tumors: ~1.8% of CpG islands hypermethylated.
  • p53-deficient tumors: ~1.1% hypermethylated.
  • Pten-deficient tumors: ~0.3% hypermethylated.

This suggests that a powerful genetic hit, such as the loss of Pten, reduces the "epigenetic pressure" on the tumor, as the genetic mutation itself bypasses the need for many secondary epigenetic silencing events.

Discussion and Implications

The data provide experimental evidence for a causal role of DNA hypermethylation in tumor progression, driven by the genetic configuration of the tumor cells. This explains the vast epigenetic heterogeneity seen in human cancers: different mutations create different selective environments, leading to unique patterns of gene silencing.

While mouse models offer a controlled environment, human cancers are more complex. However, the ability to predict a tumor's epigenetic landscape based on a few key genetic mutations suggests a future where tumors can be more accurately classified, allowing for better-targeted therapeutic interventions.

Summary updated

Abstract

Hypermethylation of CpG islands is a common epigenetic alteration associated with cancer. Global patterns of hypermethylation are tumor-type specific and nonrandom. The biological significance and the underlying mechanisms of tumor-specific aberrant promoter methylation remain unclear, but some evidence suggests that this specificity involves differential sequence susceptibilities, the targeting of DNA methylation activity to specific promoter sequences, or the selection of rare DNA methylation events during disease progression. Using restriction landmark genomic scanning on samples derived from tissue culture and in vivo models of T cell lymphomas, we found that MYC overexpression gave rise to a specific signature of CpG island hypermethylation. This signature reflected gene transcription profiles and was detected only in advanced stages of disease. The further inactivation of the Pten, p53, and E2f2 tumor suppressors in MYC-induced lymphomas resulted in distinct and diagnostic CpG island methylation signatures. Our data suggest that tumor-specific DNA methylation in lymphomas arises as a result of the selection of rare DNA methylation events during the course of tumor development. This selection appears to be driven by the genetic configuration of tumor cells, providing experimental evidence for a causal role of DNA hypermethylation in tumor progression and an explanation for the tremendous epigenetic heterogeneity observed in the evolution of human cancers. The ability to predict genome-wide epigenetic silencing based on relatively few genetic alterations will allow for a more complete classification of tumors and understanding of tumor cell biology.
BibTeX
@inproceedings{opavsky2005cpg,
  author = {René Opavský and Shu‐Huei Wang and Prashant Trikha and Aparna Raval and Yuan Huang and Yue-Zhong Wu and Blanca Rodríguez and B Keller and Sandya Liyanarachchi and Wei Guo and Ramana V. Davuluri and Michael I. Weinstein and Dean W. Felsher and Michael C. Ostrowski and Gustavo Leone and Christoph Plass},
  title = {{CpG Island Methylation in a Mouse Model of Lymphoma Is Driven by the Genetic Configuration of Tumor Cells}},
  booktitle = {PLoS},
  year = {2005},
}
Figure